Could stem cells from the placenta heal stubborn diabetic wounds?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with Type 2 Diabetes mellitus (DM) - for at least 1 year * Unilateral non-healing Diabetic Foot Ulcer (DFU) \> 2 cm2 and ≤ 4 cm2 (length × width) for at least four weeks despite Atrium Health Wake Forest Baptist standard of care treatment (which can include total contact cast, knee high air cast, and/or compression wrap) * No new diabetes medication for at least 2 weeks pre-treatment * Subjects must be willing to avoid steroids for the week prior to procedure day Exclusion Criteria: * Clinical signs of active infection requiring systemic antibiotic therapy less than 7 days prior to enrollment. * Radiographic or clinical evidence of active and untreated osteomyelitis at the target ulcer site. Current use of systemic immunosuppressive therapy, including chronic corticosteroids (equivalent to \>10 mg/day prednisone for \>14 days). * Hemoglobin (Hgb) A1C \>12.0 at screening or time in range for the blood glucose level (TIR) less than 30%. Hb A1c should not be used for patient with hypoalbuminemia or anemia in the past 3 months and for patients with Chronic Kidney disease stage 4. For patients who have Continuous Glucose Monitor (CGM), instead of Hb A1c, TIR (time in range) less than 30 % will be used. * Patients who are unable / unwilling to tolerate an effective offloading approach. This includes total contact cast, soft felted cast or knee high fracture boot. * Current alcohol or substance abuse that, in the opinion of the investigators, would interfere with study participation. * Active malignancy or malignancy related limb amputation. * Women that are pregnant or planning to become pregnant during the study. * Patients with albumin levels less than 3.5 or prealbumin levels less than 18. * Subjects with any conditions that the clinical Investigator believes may jeopardize the safety of the patient to participate in the trial. * Severe peripheral arterial disease (PAD) (Ankle-Brachial Index (ABI) less than 0.5) or TCOM (Transcutaneous Oximetry Measurement) less than 40 mmHg. * TWSB \> 30 cm2 (total wound surface burden)